FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the field of pharmacology and medicine and is aimed at treating diseases caused by betacoronaviruses, including SARS-CoV-2. Described is an application of an oxygen-containing derivative of 6-haloquinoline by the general formula I, wherein Hal constitutes a substituent selected from bromine, fluorine, chlorine; R1 constitutes a substituent selected from hydrogen, an alkyl (C1-C10) of a normal or branched structure, an aryl without substituents or substituted in positions 2, 3, 4, 5, 6; R2 constitutes a substituent selected from hydrogen, NHalkyl-, NHaryl-, NHhetaryl-, pyrrolidinyl-, piperidinyl-, morpholinyl-, piperazinyl-, homopiperazinyl-, tetrahydroquinolinyl-, tetrahydroisoquinolinyl-, hexamethyleneiminyl-; -SC(S)X, wherein X=NHalkyl-, NHaryl-, NHhetaryl-, pyrrolidinyl-, piperidinyl-, morpholinyl-, piperazinyl-, homopiperazinyl-, tetrahydroquinolinyl-, tetrahydroisoquinolinyl-, hexamethyleneinyl-; R3 constitutes a substituent selected from hydrogen, alkyl (C1-C10) of a normal or branched structure, alkylaryl, aryl without substituents or substituted in positions 2, 3, 4, 5, 6, for suppressing the replication of betacoronaviruses.
EFFECT: ensured effective suppression of the replication of betacoronaviruses, including SARA-CoV-2, at low values of the effective concentration of EC50, low cytotoxicity, and high value of selectivity index.
5 cl, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING OXYGEN-CONTAINING DERIVATIVE OF 6-HALOGENQUINOLINE FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2 | 2021 |
|
RU2827892C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING OXYGEN-CONTAINING DERIVATIVE OF 6-HALOGENQUINOLINE, FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD FOR USE THEREOF | 2021 |
|
RU2827893C1 |
| APPLICATION OF A DERIVATIVE OF 1,3,5-TRIAZINE-2,4-DIAMINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780249C1 |
| APPLICATION OF A TRICYCLIC SULPHUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780247C1 |
| PHARMACEUTICAL COMPOSITION, INCLUDING TRICYCLIC SULFUR-CONTAINING 1,2-DIHYDROQUINOLINE DERIVATIVE FOR INHIBITION OF REPLICATION OF BETA CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF ITS USE | 2021 |
|
RU2814434C1 |
| METHOD OF PRODUCING A TRICYCLIC SULFUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2 | 2021 |
|
RU2819783C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING 1,3,5-TRIAZINE-2,4-DIAMINE DERIVATIVE FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF USING SAME | 2021 |
|
RU2827891C1 |
| METHOD FOR PREPARING A THIO DERIVATIVE OF PYRROLIDINE-2,5-DIONE WITH A QUINAZOLINE FRAGMENT | 2021 |
|
RU2807057C2 |
| 5,15-BIS(4'-BIS-L-TYROSINYLAMIDOPHENYL)-10,20-BIS(N-METHYLPYRIDINIUM-3'-YL)PORPHIN DIOODIDE, SHOWING THE PROPERTY OF BINDING SARS-COV-2 VIRUS S-PROTEIN | 2022 |
|
RU2784940C1 |
| 5-[4-(1,3-BENZOTHIAZOL-2-YL)PHENYL]-10,15,20-TRIS(1-METHYLPYRIDINIUM-3-YL)PORPHYRIN TRIIOODIDE, SHOWING THE BINDING PROPERTY OF THE SARS-CoV-2 VIRUS SPIKE PROTEIN | 2021 |
|
RU2773397C1 |
